Industry · Life sciences & MedTech
Regulated product companies write a lot of controlled documentation. We build drafting, review and knowledge systems that respect GxP. People stay accountable, and an inspector can follow the audit trail.
- Focus
- Adjacent
- Value streams
- 03
- Use cases
- 09
- Related services
- 03

01Context
In life sciences and MedTech, writing often sets the time from data to submission. Clinical and technical documentation, deviations, CAPAs, change controls and regulatory responses. Each must be consistent with hundreds of other controlled documents.
AI can draft, cross-check and retrieve quickly. In a GxP environment this helps only under three conditions. The system is validated for its intended use, changes are controlled, and a qualified person reviews each output. We design to that standard from the start.
313
MedTech, biotech and pharma stakeholders in Geneva.
Source: ge.ch, key sectors
Value streams
- 01Regulatory affairs
- 02Quality and compliance
- 03Scientific knowledge
02Value streams
Each stream is a chain of work we can put agents on, with people deciding where judgement matters.
Submissions and responses drafted from controlled sources.
Use cases
- 01.1Section drafting for technical files and dossiers from source reports
- 01.2Health authority question triage and response drafting
- 01.3Consistency checks across submission documents
Deviations and CAPAs investigated and documented faster.
Use cases
- 02.1Deviation report drafting and similar-event search
- 02.2Root-cause analysis support across batch and equipment records
- 02.3SOP impact analysis for change controls
Internal and published evidence, easy to find and cited.
Use cases
- 03.1Literature monitoring and structured summaries
- 03.2Q&A across study reports and internal research
- 03.3Medical information response drafting
03Compliance notes
We design the controls from the first sprint onwards.
Computerised system validation approach aligned with GAMP 5 principles for GxP-relevant uses.
Change control for models, prompts and retrieval sources. An eval regression triggers revalidation.
Qualified-person review and e-signature on each controlled output.
Health data and genetic data treated as sensitive personal data under nFADP.
04Related work
Client withheld under NDA. Details are anonymised and combined so that no client can be identified; metrics are those measured on the engagement.
05Related services
Next step
Tell us about one process that takes your team a lot of time. Happy to have a 30-minute call, no preparation needed.





